Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

17944

Sigma-Aldrich

1α,25-Dihydroxyvitamin D2

≥97.0% (sum of vitamin and previtamin, HPLC)

Sinónimos:

1α,25-Dihydroxycalciferol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C28H44O3
Número de CAS:
60133-18-8
Peso molecular:
428.65
Beilstein/REAXYS Number:
5635017
MDL number:
MFCD00869499
UNSPSC Code:
12352205
PubChem Substance ID:
57647692
NACRES:
NA.79

biological source

synthetic

Quality Level

200

assay

≥97.0% (sum of vitamin and previtamin, HPLC)

form

crystals

color

white to light yellow

storage temp.

−70°C

SMILES string

C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C28H44O3/c1-18(9-10-19(2)27(4,5)31)24-13-14-25-21(8-7-15-28(24,25)6)11-12-22-16-23(29)17-26(30)20(22)3/h9-12,18-19,23-26,29-31H,3,7-8,13-17H2,1-2,4-6H3/b10-9+,21-11+,22-12-/t18-,19+,23-,24-,25+,26+,28-/m1/s1

InChI key

ZGLHBRQAEXKACO-XJRQOBMKSA-N

Biochem/physiol Actions

Ergocalciferol (vitamin D2) is activated in vivo by hydroxylation to 25-hydroxyergocalciferol and 1α,25-dihydroxycalciferol. Activated Vitamin D2 molecules may be used in a wide range of studies to assess their effects on functions such as immune function and calcium homeostasis.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

related product

Referencia del producto
Descripción
Precios

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
SLCC2740
SLBZ9135
BCBJ6274V
0710335171
SLBH8677V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Qing Wang et al.
Journal of cellular biochemistry, 89(6), 1087-1101 (2003-08-05)
Recent studies revealed that the MEK/ERK module of the mitogen-activated protein kinase (MAPK) signaling cascades is up-regulated in the early stages of 1alpha,25-dihydroxyvitamin D(3) (1,25D(3))-induced monocytic differentiation of human leukemia cells HL60. In the present study, we investigated whether another
Yuki Nagata et al.
Endocrine, 40(2), 315-317 (2011-08-09)
N-terminal propeptide of type I procollagen (PINP) is a marker of newly formed type I collagen. However, its role in hypophosphatemic rickets/osteomalacia has not yet been established. Metabolic bone markers were examined in patients with oncogenic osteomalacia (OOM) and X-linked
Joanna Wietrzyk et al.
Cancer chemotherapy and pharmacology, 62(5), 787-797 (2008-01-12)
Active and less toxic vitamin D analogs could be useful for clinical applications. In the present study, we evaluated the toxicity and antitumor effect of two new synthetic analogs of vitamin D, namely PRI-1906 [(24E)-24a-Homo-(1S)-1,25-dihydroxyergocalciferol] and its side-chain unsaturated homo
Hanna Baurska et al.
Oncology reports, 28(3), 1110-1116 (2012-07-04)
1,25-Dihydroxyvitamin D3 (1,25D) is implicated in many cellular functions including cell proliferation and differentiation, thus, exerting potential antitumor effects. A major limitation for therapeutic use of 1,25D are its potent calcemic and phosphatemic activities. Therefore, synthetic analogs of 1,25D for
Joanna Wietrzyk et al.
Oncology research, 16(11), 517-525 (2008-03-01)
New vitamin D analogs are interesting candidates for anticancer treatment, including squamous cell carcinomas (SCCs), especially in combination with cytostatics. In order to evaluate the effect of combined application of cisplatin, imatinib, or docetaxel and new vitamin D analogs [PRI-1906:
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico